The Aptima HPV assay, utilizing target capture and transcription-mediated amplification technology, detects the presence of messenger RNA (mRNA) from high-risk human papillomavirus (HPV) types 16, 18, and 45. These specific genotypes are strongly associated with the development of cervical cancer. This test differs from DNA-based tests by identifying active viral transcription, offering insight into the potential for disease progression.
Detecting E6/E7 mRNA from HPV 16, 18, and 45 provides a more precise assessment of cervical cancer risk than simply identifying the presence of viral DNA. This allows for more effective triage of patients for further diagnostic procedures, such as colposcopy, and can contribute to earlier intervention and improved patient outcomes. The development of mRNA-based HPV testing represents a significant advancement in cervical cancer screening, enabling a more nuanced and targeted approach to risk stratification.
